GLP-1 for Maintenance: The Case for Lower Long-Term Doses

Every GLP-1 conversation eventually arrives at the same uncomfortable question: what happens after you reach goal weight? The standard trial protocol — stay on the full dose indefinitely — collides with reality the moment you look at a pharmacy receipt or a side-effect diary. So a middle path has emerged in clinical practice: keep taking the medication, but at a lower dose or longer interval than the one that got you there.

This article examines the evidence for that middle path honestly: what the withdrawal trials prove, what the maintenance-dose data actually shows (less than you would hope), and how to think about the decision with your prescriber. Note that this is not an article about quitting GLP-1s entirely — that is a different decision with its own playbook. This is about the case for staying on, smaller.

The problem maintenance dosing tries to solve

The regain data is the strongest, most repeatable finding in the entire GLP-1 literature. In the STEP 1 extension study, participants who stopped semaglutide 2.4 mg regained roughly two-thirds of their lost weight within a year of their last dose. STEP 4 made the comparison directly: after 20 weeks on full-dose semaglutide, participants randomized to continue lost an additional 7.9% of body weight over the next 48 weeks, while those switched to placebo regained 6.9%. SURMOUNT-4 repeated the design with tirzepatide and found the same shape — continuing produced further loss of about 5.5%, while withdrawal produced roughly 14% regain.

The interpretation major medical bodies draw from this is that obesity behaves like a chronic disease — a position the American Medical Association formalized back in 2013 — and chronic diseases generally require ongoing treatment. Nobody is surprised when blood pressure rises after stopping an antihypertensive. The regain curves say appetite regulation works the same way.

Why “full dose forever” is a hard sell anyway

Three forces push against permanent maximum dosing. Cost: US list prices for branded GLP-1s have run roughly $1,000–1,350 per month before insurance, and coverage for maintenance-phase use is patchier than for active weight loss. Side effects: gastrointestinal effects are dose-related; in STEP trials, nausea affected around 44% of participants on 2.4 mg semaglutide at some point, and a meaningful minority of real-world users report they would tolerate the drug better one notch down. Simple drug exposure: the lowest effective dose is a foundational principle of pharmacology, endorsed across prescribing guidelines.

If a lower dose can hold a defended weight in place, all three problems shrink at once. The question is whether it can.

What the evidence actually says about lower maintenance doses

Here is the candid part: the dedicated trial you want — reach goal on a full dose, then randomize people to full dose, reduced dose, or placebo and watch for two years — has not been published. What exists instead is indirect but not empty:

Dose-response data. Semaglutide 1.0 mg (the Ozempic-tier dose) produced roughly 6–7% weight loss in trials versus about 15% at 2.4 mg. Lower doses are not inert; they carry real appetite-regulating effect. Holding weight requires less pharmacological force than losing it, because you are no longer fighting an active deficit — only the body’s defense of its new weight.

Withdrawal-trial asymmetry. In STEP 4 and SURMOUNT-4, regain on placebo was rapid but not instant — it built over months. That suggests the medication’s effect fades gradually with dose, rather than switching off below a threshold, which is consistent with partial doses providing partial protection.

Real-world practice. Obesity-medicine clinicians widely report maintaining patients on reduced doses or stretched intervals (for example, a weekly pen taken every 10–14 days), and early observational reports suggest many patients hold their weight this way. But observational reports of motivated patients are the weakest tier of evidence, and stretched intervals are an off-label adjustment that belongs entirely in a prescriber’s hands — especially since these drugs’ pharmacokinetics (semaglutide’s half-life is about one week) were designed around weekly dosing.

The three maintenance strategies, compared

Strategy	Evidence strength	What the data shows
Continue full dose	Strong (RCTs)	Best-supported: STEP 4 and SURMOUNT-4 continuers kept losing or held weight; highest cost and side-effect load
Step down to a lower dose	Moderate-to-weak (dose-response logic + practice reports; no dedicated RCT)	Plausible and increasingly common; expect some regain risk and plan monitoring
Stop entirely	Strong evidence of regain	~Two-thirds of lost weight regained within a year in STEP 1 extension; works long-term for a minority with strong lifestyle scaffolding

How to run a step-down experiment responsibly

If you and your prescriber decide to try a lower maintenance dose, structure it like the experiment it is:

1. Stabilize first. Hold goal weight on your current dose for 2–3 months before changing anything.
2. Change one variable. Drop one dose tier — not two — and keep food, activity and sleep patterns steady so you can read the result.
3. Set a tripwire in advance. A common approach is a 3–5 lb (about 2 kg) regain threshold that automatically triggers a return to the previous dose. Deciding this before you start removes wishful thinking later.
4. Weigh weekly, not daily. You are watching for a trend over 4–8 weeks, not noise.
5. Keep the behavioral floor. Protein targets, resistance training and sleep are what the medication was scaffolding; they matter more, not less, at lower doses.
6. Review at 12 weeks. Held steady? You have found a cheaper, gentler maintenance dose. Regained past the tripwire? You have learned your defended dose — that is a success too, not a failure.

The verdict

The case for lower long-term dosing is built on solid indirect evidence and thin direct evidence. What is proven: stopping entirely leads to substantial regain for most people, and continuing at full dose prevents it. What is plausible but unproven at trial level: that an intermediate dose holds an intermediate — often sufficient — line. Given the cost and tolerability advantages, a monitored step-down is a reasonable, increasingly mainstream strategy, provided it is run with a prescriber, a scale and a pre-agreed tripwire. What the evidence does not support is the quiet DIY version: stretching doses to save money without monitoring, then discovering the regain six months later.

Is taking a GLP-1 every two weeks safe?

Interval-stretching is an off-label modification with limited published data. Some clinicians use it deliberately in maintenance; it should never be improvised without your prescriber, both for safety and because erratic dosing can reintroduce start-up side effects.

Will insurance cover a maintenance dose?

Often the harder problem. Some plans require documented active weight loss or a minimum BMI for continued coverage, and stepping down can complicate prior authorizations. Ask your prescriber’s office to check before changing the regimen.

How fast would I regain on a lower dose if it isn’t enough?

Withdrawal-trial curves suggest regain builds over weeks to months rather than days — which is exactly why a weekly weigh-in with a pre-set threshold catches an insufficient dose early, while the fix is still small.

Does everyone need lifelong medication?

No — a minority maintain large losses after stopping, typically with intensive lifestyle structure. But the honest base rate from trials is that most people regain most of the weight, so plan for maintenance and be pleasantly surprised, not the reverse.